Literature DB >> 16977568

Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.

Jan J Michiels1, Zwi Berneman, Alain Gadisseur, Marc van der Planken, Wilfried Schroyens, Ulrich Budde, Huub H D M van Vliet.   

Abstract

The most common nonimmune etiology of acquired von Willebrand syndrome (AvWS) includes hypothyroidism, Wilms' tumor, thrombocythemia, or congenital heart defects, and the use of various drugs. AvWS type 1 in patients with hypothyroidism is due to decreased Willebrand factor (vWF) synthesis and is reversible by treatment with thyroxin. AvWS type 1 or 3 in children with Wilms' tumor disappears after successful chemotherapy or tumor resection but the mechanism of the vWF deficiency is unknown. The AvWS type 2 in patients with thrombocythemia of various myeloproliferative disorders is caused by increased proteolysis of large vWF multimers at increasing platelet counts to above 1000 x 10 (9)/L. Reduction of platelet counts to normal results in correction of the vWF parameters together with disappearance of the bleeding tendency. Type 2-like AvWS in children with congenital heart valve defects is caused by shear stress-induced proteolysis of large vWF multimers and is reversible after surgical correction. AvWS associated with the use of drugs disappears after discontinuation of the causative agent. Immune-mediated AvWS is associated with either systemic lupus erythematosus (SLE) or immunoglobulin G (IgG) benign monoclonal gammopathy (BMG), and usually shows a type 2 vWF deficiency. Using a simple enzyme-linked immunosorbent assay, an IgG antibody against vWF is detectable in AvWS associated with SLE and IgG BMG. The IgG-autoantibody-factor (F) vWF/VIII complex is rapidly cleared from the circulation, which explains the combined FVIII:coagulant activity (C) and vWF deficiency and the poor responses of FVIII:C and vWF parameters to intravenous desmopressin acetate and vWF/FVIII concentrates. A transient correction of both FVIII:C and vWF parameters to normal for a few weeks after high-dose intravenous immunoglobulin is seen in AvWS associated with SLE and IgG BMG. AvWS associated with SLE uniformly shows a curative response to corticosteroids. AvWS associated with IgG BMG does not respond to corticosteroids, immune suppression, or chemotherapy. AvWS associated with IgM BMG is rare and does not respond to any conventional treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16977568     DOI: 10.1055/s-2006-949663

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  9 in total

Review 1.  Narrative review: the systemic capillary leak syndrome.

Authors:  Kirk M Druey; Philip R Greipp
Journal:  Ann Intern Med       Date:  2010-07-20       Impact factor: 25.391

2.  Acquired von Willebrand syndrome in a 10-year-old girl with acute lymphoblastic leukaemia.

Authors:  Isabel Dorn; Ulrich Budde; Michael C Frühwald; Monika Pöppelmann; Ulrike Nowak-Göttl
Journal:  BMJ Case Rep       Date:  2009-06-21

3.  [Cancer-associated coagulation disorders].

Authors:  Minna Voigtländer; Florian Langer
Journal:  Dermatologie (Heidelb)       Date:  2022-09-14

Review 4.  [Idiopathic systemic capillary leak syndrome (Clarkson disease) : A rare cause of recurrent life-threatening edema].

Authors:  S Dasdelen; S-O Grebe
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

Review 5.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

6.  Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus.

Authors:  Sara Taveras Alam; Karenza Alexis; Ashwin Sridharan; Marianna Strakhan; Tarek Elrafei; Richard J Gralla; Louis J Reed
Journal:  Case Rep Hematol       Date:  2014-12-07

7.  Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.

Authors:  Eva Jennes; Dorothee Guggenberger; Rainer Zotz; Lora Thompson; Tim H Brümmendorf; Steffen Koschmieder; Edgar Jost
Journal:  Clin Case Rep       Date:  2017-03-30

8.  Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management.

Authors:  Mouhamed Yazan Abou-Ismail; George M Rodgers; Paul F Bray; Ming Y Lim
Journal:  Res Pract Thromb Haemost       Date:  2021-02-17

9.  Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus.

Authors:  Christina Dicke; Katharina Holstein; Sonja Schneppenheim; Rita Dittmer; Reinhard Schneppenheim; Carsten Bokemeyer; Christof Iking-Konert; Ulrich Budde; Florian Langer
Journal:  Exp Hematol Oncol       Date:  2014-08-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.